GlassScriptPhysician profile
Katherine Mamo
NPI 1679234934
$20,647.04
in general payments reported to CMS, 2019-2025
38 companies · $6,626 in 2025
The $6,626 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,143 · 2023: $5,330 · 2024: $4,548 · 2025: $6,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,230.46 |
| Education | $273.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,162.48 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $3,069.53 | 2022-2025 | Tavneos, Enbrel, Amjevita |
| Abbvie INC. | $2,624.47 | 2022-2025 | |
| Ucb, INC. | $2,461.65 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,430.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,148.67 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $937.41 | 2022-2025 | Orencia |
| Lilly USA, LLC | $770.86 | 2022-2025 | Taltz, Zepbound |
| Organon LLC | $425.91 | 2023-2025 | Hadlima, Renflexis |
| Janssen Scientific Affairs, LLC | $395.11 | 2022-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $376.29 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.80 | 2022-2025 | Ofev, Cyltezo |
| Horizon Therapeutics Plc | $320.29 | 2022-2023 | Krystexxa |
| Pfizer INC. | $303.80 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $227.57 | 2023-2025 | Idacio |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $211.52 | 2022-2023 | Lupkynis |
| Radius Health, INC. | $200.94 | 2022-2025 | Tymlos |
| Alvogen INC | $184.70 | 2022-2025 | Teriparatide |
| Mallinckrodt Hospital Products INC. | $171.95 | 2023 | Acthar |
| Sobi, INC | $170.55 | 2022-2025 | |
| Sandoz INC. | $153.59 | 2023-2025 | Hyrimoz, Jubbonti |
| Genzyme Corporation | $66.77 | 2023-2025 | |
| Kyowa Kirin, INC. | $44.12 | 2023-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $43.40 | 2022-2025 | Strensiq |
| Daiichi Sankyo INC. | $41.13 | 2023 | Injectafer |
| Lundbeck LLC | $40.36 | 2022 | |
| Ferring Pharmaceuticals INC. | $38.33 | 2023 | Euflexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $37.42 | 2022 | |
| Mylan Institutional INC. | $36.19 | 2023 | Hulio |
| Actelion Pharmaceuticals US, INC. | $28.48 | 2022-2023 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $27.22 | 2023 | Benlysta |
| Tonix Medicines, INC. | $23.75 | 2025 | Tonmya |
| Tersera Therapeutics LLC | $23.51 | 2024 | Quzyttir |
| Biocon Biologics INC | $17.91 | 2024 | Hulio |
| Fidia Pharma USA INC. | $15.89 | 2022 | |
| Leo Pharma INC. | $14.93 | 2025 | Anzupgo |
| Genentech USA, INC. | $13.75 | 2025 | Actemra |
| Ibsa Pharma INC. | $13.42 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.